HEALTH PLANS
UNIVERSITY OF UTAH

PRIOR AUTHORIZATION REQUEST FORM

VMAT-2 INHIBITORS

Austedo®, Ingrezza®, Xenazine®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: ☐ Austedo® (deutetrabenazine), ☐ Ingrezza® (valbenazine), ☐ Xenazine® (tetrabenazine)

Dosing/Frequency:____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
TARDIVE DYSKINESA			
1. Does documentation contain an Abnormal Involuntary Movement Scale (AIMS)?	☐	☐	**Please provide documentation**
2. Does the member contain e a Clinical Global Impression of Severity (CGI-S)?	☐	☐	**Please provide documentation**
3. Has the member had 3-month trial and failure of a benzodiazepine?	☐	☐	**Please provide documentation**
4. Is the member currently taking reserpine or a MAO-I?	☐	☐	
5. For Ingrezza®, has the member had a 3-month trial and failure of Austedo®?	☐	☐	**Please provide documentation**
CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE			
1. Is the requesting prescriber a neurologist?	☐	☐	
2. Has the member tried and failed at least two of the following: amantadine, an antipsychotic, Rilutek®, or Cesamet®?	☐	☐	**Please provide documentation**
3. For Xenazine®, has the member had a 3-month trial and failure of Austedo®?	☐	☐	**Please provide documentation**
TOURETTE SYNDROME			
1. Have non-pharmacologic therapies been tried and found to be inadequate to meet treatment goals?	☐	☐	**Please provide documentation**

Confidentiality Notice
This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

2. Has the member tried and failed at least 3 of the following medications: guanfacine, clonidine, topiramate, baclofen, benzodiazepines, ropinirole, botulinum toxin, fluphenazine, haloperidol, risperidone, pimozide, ziprasidone, aripiprazole?	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy for tardive dyskinesia?	☐	☐	
2. Does clinical documentation show a continued medical need as well as medication efficacy defined by the AIMS score has decreased by at least 2 points from based line and the CGI-S score ≤ 2?	☐	☐	**Please provide documentation**
3. Does clinical documentation show a continued medical need as well as medication efficacy?	☐	☐	**Please provide documentation**
4. Is the request for reauthorization of therapy for Huntington's disease?	☐	☐	
5. Does updated documentation show disease stabilization and functional improvement of symptoms?	☐	☐	**Please provide documentation**
6. Does clinical documentation show a continued medical need as well as medication efficacy defined as objective progress towards treatment plan goals? Does the member have disease stabilization and functional improvement of symptoms?	☐	☐	**Please provide documentation**
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 076
Origination Date: 03/21/2018
Reviewed/Revised Date: 03/20/2019
Next Review Date: 03/20/2020
Current Effective Date: 03/20/2019

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.